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Epstein-Barr virus (EBV) establishes a latent form of infection in memory B cells, while antibody-secreting
plasma cells often harbor the lytic form of infection. The switch between latent and lytic EBV infection is
mediated by the two viral immediate-early proteins BZLF1 (Z) and BRLF1 (R), which are not expressed in
latently infected B cells. Here we demonstrate that a cellular transcription factor that plays an essential role
in plasma cell differentiation, X-box-binding protein 1 (XBP-1), also activates the transcription of the two EBV
immediate-early gene promoters. In reporter gene assays, XBP-1 alone was sufficient to activate the R
promoter, whereas the combination of XBP-1 and protein kinase D (PKD) was required for efficient activation
of the Z promoter. Most importantly, the expression of XBP-1 and activated PKD was sufficient to induce lytic
viral gene expression in EBV-positive nasopharyngeal carcinoma cells and lymphoblastoid cells, while an
XBP-1 small interfering RNA inhibited constitutive lytic EBV gene expression in lymphoblastoid cells. These
results suggest that the plasma cell differentiation factor XBP-1, in combination with activated PKD, can
mediate the reactivation of EBV, thereby allowing the viral life cycle to be intimately linked to plasma cell
differentiation.
Epstein-Barr virus (EBV) is the causative agent of infectious
mononucleosis and is associated with B-cell lymphomas, naso-
pharyngeal carcinomas, gastric carcinomas, and other malig-
nancies (26, 45). EBV causes lytic infection in normal oral
epithelial cells (32, 51) while usually establishing one of the
latent forms of infection in circulating memory B cells. In
contrast, tonsillar B cells that express antigens specific for
plasma markers commonly harbor the lytic form of EBV in-
fection, which results in the production of infectious viral par-
ticles (10, 29, 30).
The switch from latent to lytic EBV infection is mediated by
the immediate-early (IE) protein BZLF1 (Z) and the imme-
diate-early/early protein BRLF1 (R) (1, 16, 57). Z and R are
transcription factors that activate each other’s transcription
and together are sufficient to activate the entire lytic viral gene
expression cascade (17, 49). In latently infected cells, the pro-
moters driving Z and R expression (Zp and Rp) are inactive.
Therefore, the activation of Zp and Rp by cellular transcrip-
tion factors is the crucial initial step required for lytic viral gene
expression. B-cell receptor engagement activates lytic EBV
gene expression in some B-cell lines in vitro and activates both
EBV IE promoters in reporter gene assays (23). Although
several different individual cellular transcription factors can
activate one or both of the two EBV IE promoters in reporter
gene assays (23), to date these factors have not been shown to
be sufficient for the efficient reactivation of lytic viral gene
expression from the endogenous viral genome in latently in-
fected cells.
While there is a strong correlation between plasma cell dif-
ferentiation and lytic EBV gene expression in human tonsils, it
is not presently understood why this association occurs. Possi-
ble explanations include the ability of one or more lytic viral
proteins to induce plasma cell differentiation in B cells. Alter-
natively, plasma cell differentiation may result in the expres-
sion of one or more cellular transcription factors that activate
lytic viral gene expression. The human protein X-box-binding
protein 1 (XBP-1) is a basic-region leucine zipper transcrip-
tional activator protein belonging to the cyclic AMP response
element-binding protein/activating transcription factor (CREB/
ATF) family that is activated early in the process of plasma cell
differentiation and plays an essential role in this process (33,
43). We therefore hypothesized that XBP-1 may also play a
role in mediating the reactivation of lytic EBV gene expression
during plasma cell differentiation, possibly in conjunction with
one or more cellular factors activated by B-cell receptor en-
gagement.
In this work, we demonstrate that the combination of the
active (spliced) form of XBP-1 (XBP-1s) with activated protein
kinase D (PKD, a histone deacetylase [HDAC] inhibitor that is
activated following antigen receptor engagement in B cells)
(37, 52) is sufficient to induce lytic EBV gene expression in
lymphoblastoid B cells, as well as nasopharyngeal carcinoma
epithelial cells. We show that XBP-1s alone efficiently activates
Rp in reporter gene assays, while the combination of XBP-1s
and PKD is required for the activation of the other EBV IE
promoter, Zp. Furthermore, we demonstrate that a small in-
terfering RNA (siRNA) directed against XBP-1 inhibits the
low-level constitutive lytic EBV gene expression that occurs in
lymphoblastoid cells (LCLs). These results suggest that XBP-
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1s, in conjunction with activated PKD, induces the switch from
latent to lytic EBV infection in plasma cells.
MATERIALS AND METHODS
Cell lines. HONE-1/EBV is a human nasopharyngeal carcinoma cell line that
stably maintains the EBV (Akata strain) genome under G418 selection in a latent
form (47). HeLa is a malignant human epithelial cervical cancer cell line.
HONE-1/EBV cells were grown in RPMI 1640 medium (Sigma). HeLa cells
were grown in Dulbecco’s modified Eagle’s medium (Sigma). Both media were
supplemented with 10% fetal bovine serum and penicillin-streptomycin. Early-
passage LCLs (primary human B cells transformed with the B95-8 strain of EBV)
were a gift from Bill Sugden at McArdle Laboratory, University of Wisconsin,
Madison, and were grown in RPMI 1640 medium with 10% fetal bovine serum.
Plasmids. Plasmid DNA was purified through columns as described by the
manufacturer (QIAGEN). Rp-LUC contains the Rp sequence from 37 to
981 relative to the R transcription start site inserted 5 of the luciferase gene
in the pGL3-basic vector (Promega). A series of 5 deletion mutants of the
Rp-LUC construct (containing the promoter sequence from 37 to 30, 37 to
100, 37 to 197, 37 to 634, or 37 to 750) were also constructed.
Zp-LUC contains the IE Zp sequence from 28 to 495 relative to the Z
transcription start site inserted upstream of the luciferase gene in pGL3-basic.
The Zp-CAT constructs, containing Zp sequences from 221 to 12 inserted
upstream of the CAT gene or mutations in these sequences removing either the
ZII (cis-acting replication element [CRE]) or ZI (myocyte enhancer factor 2D
[MEF2D]) motifs, were a gift from Erik Flemington (Tulane University) (15).
Plasmids expressing the FLAG-tagged versions of the XBP-1s or unspliced
XBP-1 forms of mouse XBP-1 were a generous gift from Laurie Glimcher
(Harvard University). A vector expressing the constitutively active form of cal-
modulin-dependent calcium kinase IV (CaMKIV) was a generous gift from
Xiang-Jiao Yang (McGill University). A vector expressing constitutively active
PKD in which the serine residues at positions 738 and 742 have been changed to
aspartate was constructed by Alex Toker (Harvard University) and acquired
from Addgene.
Luciferase assays. HeLa cells were transfected using FuGENE 6 (Roche).
Luciferase assays were performed 48 to 72 h after transfection by using extracts
prepared by freeze-thawing the cell pellet in reporter lysis buffer according to the
instructions of the manufacturer (Promega). The luciferase activity in an assay
buffer containing 12.5 mM glycylglycine, 2 mM EGTA, 7.5 mM MgSO4, 7.5 mM
K2HPO4, 0.5 mM dithiothreitol, 1 mM ATP, 100 M luciferin, and 50 mM Tris
was determined with an Auto Lumat LB953 luminometer (EG&G Berthold).
CAT assays. HeLa cells were transfected using FuGene 6 (Roche). Cell ex-
tracts were prepared 2 days posttransfection and incubated at 37°C with
[14C]chloramphenicol (Amersham) in the presence of acetyl coenzyme A
(Roche). The percent acetylation was determined by phosphorimager screening
(Molecular Dynamics).
Immunoblot analysis. HONE-1/EBV cells were transfected using FuGene 6
(Roche); LCLs were transfected with 400 nM DNA by using a nucleofector
device (Amaxa) in buffer V with program A30. Cells were harvested 2 days
postinfection, washed twice with 1 phosphate-buffered saline, and resuspended
in a 1:3 mixture of SUMO buffer I (5% sodium dodecyl sulfate [SDS], 0.15 M
Tris-HCl [pH 6.8], 30% glycerol) and SUMO buffer II (25 mM Tris-HCl [pH
8.3], 50 mM NaCl, 0.5% NP-40, 0.5% deoxycholate, 0.1% SDS) and 1 complete
protease inhibitors (Roche). The cells were briefly sonicated and centrifuged.
The resulting supernatants were electrophoresed on a 7% SDS-polyacrylamide
gel electrophoresis denaturing gel. The proteins were transferred onto a nitro-
cellulose membrane (Protran), blocked in 1 phosphate-buffered saline–5%
milk–0.1% Tween 20, and incubated with anti-XBP-1 (rabbit; 1:500 [Santa
Cruz]), anti-R (mouse; 1:100 [Argene]), anti-Z (mouse; 1:100 [Argene]), anti-
EBV diffuse early antigen (BMRF1; mouse; 1:250 [Vector Laboratories]), or
anti--actin (1:5,000 [Sigma]) antibody for 1 h at room temperature. Vector
controls used in these experiments were either the SG5 vector or a vector
expressing an unspliceable form of XBP-1.
siRNA experiments. siRNA against the human XBP-1 message (sense, 5
ACAGCAAGUGGUAGAUUUATT, and antisense, 5 UAAAUCUACCACU
UGCUGUTT) was purchased from Ambion. Negative control siRNA was pur-
chased from Santa Cruz (SC37007). LCLs (5  106) were transfected with 400
nM XBP-1 siRNA (or control siRNA) by using a nucleofector device (Amaxa) in
buffer V with program A30. These conditions allowed at least 75% of the cells to
be transfected, with approximately 50% viability. Two days postdelivery of the
siRNA, immunoblot analysis was performed to determine the expression levels
of the early lytic EBV protein BMRF1 and -actin, whereas reverse transcriptase
(RT)-PCR analysis was performed to determine the amounts of XBP-1, Z, R,
and 2-microglobulin transcripts. PCR primers used to detect the XBP-1 tran-
script were 5 CCTTGTAGTTGAGAACCAGG and 5 GGGGCTTGGTATA
TATGTGG. RT-PCR analysis of the 2-microglobulin, Z, and R transcripts was
performed as previously described (20).
EMSA. In vitro-translated XBP-1s was made using a TNT T7 quick-coupled
transcription-translation system according to the instructions of the manufac-
turer (Promega). Electrophoretic mobility shift assay (EMSA) binding reactions
were performed with a buffer consisting of 1 mM dithiothreitol, 10 mM HEPES
(pH 7.9), 1 mM EDTA, 50 mM KCl, 2 mM MgCl2, and 5% glycerol (5, 9). Two
microliters of in vitro-translated XBP-1s from reticulocyte lysate (or the untrans-
lated reticulocyte lysate), 1 g of poly(dI-dC)/poly(dI-dC) (Pharmacia), and 1
mg of bovine serum albumin/ml were added to the binding reaction mixture, and
the mixture was incubated for 5 min at room temperature before the addition of
a labeled probe (10,000 cpm) and 20 min at room temperature after the addition
of the labeled probe. Anti-XBP-1 antibody was added to the reaction mixture,
and the mixture was further incubated at room temperature for 10 min. The
reaction mixture was then loaded onto a 4% polyacrylamide gel and run in 0.5%
Tris-borate-EDTA buffer at room temperature. The gel was dried on Whatman
3MM chromatography paper and exposed to autoradiography film (Amersham).
The film was developed using Kodak developer.
The sequences of the oligonucleotide probes used in EMSAs were as follows:
positive control, 5 CTCGAGATGGATGACGTGTACAATAAAACGTCAA
GCTT 3 (9); Zp CRE motif (54 to 73), 5 CCTCTGTGATGTCATGGTTT
3. Complementary oligonucleotides were annealed, end labeled with 32P, and
used in EMSAs.
RESULTS
The combination of XBP-1s and activated PKD is sufficient
to induce the reactivation of lytic EBV gene expression in
latently infected epithelial cells and lymphoblastoid B cells. To
determine if XBP-1 induces lytic EBV gene expression, la-
tently infected EBV-positive cell lines were transfected with
the construct expressing XBP-1s, the spliced (active) form of
the XBP-1 gene product, and lytic viral gene expression was
monitored by immunoblot analysis of two different lytic viral
proteins (BMRF1 and Z) 2 days after transfection. In addition,
the effect of the activated form of PKD was also examined
because antigen receptor engagement in B cells, which stimu-
lates lytic EBV gene expression in certain cell lines, has been
shown to convert PKD into its active form (36, 50, 60). PKD
directly phosphorylates class II HDAC proteins, causing them
to be sequestered in an inactive form with the 14-3-3 protein in
the cytoplasm (52).
As shown in Fig. 1, the transfection of cells of a latently
infected, EBV-positive nasopharyngeal carcinoma cell line
(HONE-1/EBV) (47) with the XBP-1s vector alone resulted in
low-level expression of the early lytic viral protein BMRF1,
while the PKD vector alone had no effect. However, the com-
bination of XBP-1s with activated PKD induced much more
expression of the BMRF1 and Z lytic viral proteins than
XBP-1s alone. Similar to that in nasopharyngeal carcinoma
cells, XBP-1s alone activated low-level expression of the early
viral protein BMRF1 in early-passage EBV-immortalized B-
cell line LCLs, although the XBP-1s–PKD combination was
clearly more effective (Fig. 2). There was no detectable level of
Z in cells transfected with XBP-1s alone, while XBP-1s and
PKD together significantly activated Z expression. In addition,
XBP-1s in combination with PKD significantly activated the
expression of the immediate-early/early R protein compared
with the low level of R induced by XBP-1s alone. These results
indicate that the combination of XBP-1 and activated PKD is
sufficient to reactivate lytic EBV gene expression in either a
B-cell or epithelial-cell environment.
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XBP-1s alone is sufficient to activate the EBV IE promoter
Rp in reporter gene assays, while the combination of XBP-1
and PKD activates Zp. To determine if XBP-1s or activated
PKD (alone or in combination) can activate either of the two
EBV IE promoters, HeLa cells were transfected with reporter
gene constructs containing Rp or Zp driving the luciferase
gene and a vector control, the XBP-1s expression vector alone,
the PKD expression vector alone, or the combination of both
XBP-1s and PKD (Fig. 3). XBP-1s by itself strongly increased
the activity of the Rp IE promoter, and this effect was not
further enhanced by the addition of PKD. In contrast, the
combination of XBP-1s and the constitutively active form of
PKD produced more Zp activity than that induced by PKD or
XBP-1s alone. A vector expressing the unspliced (inactive)
form of the mouse XBP-1 gene product did not enhance Rp or
Zp activity (data not shown). These results indicate that XBP-1
alone efficiently activates Rp but not Zp and that PKD aug-
ments the XBP-1s-mediated activation of the Zp.
XBP-1s activates Rp indirectly. Neither Rp nor Zp contains
a consensus XBP-1-binding motif. To map the XBP-1s-respon-
sive region(s) in Rp, a series of 5 deletion mutations in the
Rp-LUC vector were constructed. Rp sequences located be-
tween 750 and 634 and between 197 and 100 were both
important for XBP-1s activation of the promoter (Fig. 4). In
vitro-translated XBP-1s did not bind to any of a series of
overlapping probes spanning the two XBP-1s-responsive Rp
elements in EMSAs, although it clearly bound to a positive
control probe containing the consensus XBP-1-binding motif
(data not shown and Fig. 5B). These data suggest that XBP-1s
activates Rp via an as-yet-unknown indirect mechanism.
PKD reverses the inhibitory effect of MEF2D motifs in Zp.
To further examine why PKD is required for efficient XBP-1s
activation of the Zp promoter, we examined the effect of mu-
tating the MEF2D (ZI)-binding motifs in Zp (5, 52), which
have previously been shown to inhibit Zp activity when
MEF2D interacts with class II HDACs (5, 15). As shown in
Fig. 5A, a vector containing the wild-type Zp (from 221 to
12) linked to the CAT reporter gene responded minimally to
XBP-1s or PKD alone but was efficiently activated by the
XBP-1s–PKD combination. In contrast, when two MEF2D-
binding motifs in Zp-CAT were mutated, the ability of XBP-1s
alone to stimulate the promoter was enhanced, and the com-
bination of PKD and XBP-1s together was no more effective
than XBP-1s alone. These results indicate that the MEF2D
sites act to inhibit XBP-1s activation of Zp and that PKD
reverses this effect.
FIG. 1. XBP-1s and PKD synergistically activate lytic EBV gene
expression in HONE-1/EBV cells. HONE-1/EBV cells were trans-
fected with empty vector (), XBP-1s, constitutively active PKD
(PKD), or the combination of XBP-1s and PKD. Immunoblot analysis
of cellular extracts was performed 2 days later to quantitate the ex-
pression of two different lytic EBV proteins (Z and BMRF1), a cellular
protein (-actin), and transfected XBP-1s protein. , present.
FIG. 2. XBP-1s and PKD synergistically activate lytic EBV gene
expression in early-passage LCLs. LCLs were transfected with empty
vector (), the XBP-1s expression vector, constitutively active PKD
(PKD), the combination of XBP-1s and PKD, or a Z expression vector.
Immunoblot analysis of cellular extracts was performed 2 days later to
quantitate the expression of the lytic EBV proteins (BMRF1, R, and
Z) and cellular -actin. , present; LCL/EBV, EBV-infected LCLs.
FIG. 3. XBP-1s and PKD activation of Rp versus Zp. HeLa cells
were transfected with vectors containing the luciferase (Luc) gene
linked to either the R (Rp-LUC) or Z (Zp-LUC) promoter in combi-
nation with either a control plasmid (), an XBP-1s expression vector,
a constitutively active form of PKD (PKD), or both XBP-1s and PKD,
as indicated. Luciferase activity was measured 2 days later. Results are
presented as the increase (n-fold) in the amount of luciferase activity
after transfection with XBP-1s, PKD, or both compared with the
amount of activity after transfection with the control vector, as indi-
cated. , present.
FIG. 4. XBP-1-responsive regions in Rp. Various 5 deletions in
Rp-LUC were constructed as indicated, and HeLa cells were trans-
fected with the constructs in combination with either empty vector ()
or the vector expressing XBP-1s (). Results are presented as the
increase (n-fold) in the amount of luciferase activity after transfection
with XBP-1s versus the vector control for each promoter construct.
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In addition to MEF2D, Zp activity is positively regulated by
a CRE motif (ZII) and negatively regulated by a ZEB-binding
site (ZV). The mutation of the CRE (ZII) site in Zp, which has
been previously shown to be bound by ATF1, ATF2, CREB,
and c-jun (23), decreased Zp activation by the XBP-1s–PKD
combination, suggesting that the CRE motif is required for an
efficient XBP-1s–PKD effect (Fig. 5A). However, we found
that XBP-1s binds only weakly, if at all, to the Zp CRE motif
in EMSAs (Fig. 5B). The mutation of the Zp ZEB-binding site
(in the context of the Zp-LUC construct) enhanced the ability
of the XBP-1s–PKD combination to activate Zp (Fig. 5C).
These results confirm that ZEB binding to Zp, as previously
described (28), acts as a negative regulator of Zp activity.
CaMKIV and valproic acid also augment the ability of
XBP-1s to induce EBV reactivation. The two isoforms of PKD
expressed in B cells are thought to account for the majority of
class II HDAC inhibitory activity in uninfected B cells (11, 21,
37). However, as PKD affects a number of cellular pathways in
addition to HDAC proteins (3, 8, 19, 35, 39, 48), we deter-
mined if other HDAC inhibitors could likewise augment
the ability of XBP-1s to induce lytic EBV gene expression.
CaMKIV, like activated PKD, directly phosphorylates class II
HDAC proteins and inhibits their function (34, 38). Although
CaMKIV is not normally expressed in B cells, its transcription
is induced by a latent EBV protein, LMP-1 (40), and B-cell
FIG. 5. MEF2D and CRE motifs contribute to XBP-1s–PKD
activation of Zp. (A) HeLa cells were cotransfected with reporter
gene constructs containing the wild-type Zp (221 to 12) inserted
upstream of the CAT gene or containing site-directed mutations in
the Zp altering the MEF2D or CRE motifs and either a vector
control or the XBP-1s expression vector. CAT activity was quanti-
tated 2 days later. Results are presented as the increase (n-fold) in
the amount of CAT activity after transfection with XBP-1s com-
pared with the amount of activity after transfection with the control
vector as indicated for each promoter construct. , present; ,
absent. (B) EMSA was performed using in vitro-translated XBP-1s
() or untranslated rabbit reticulocyte lysate () in combination
with either the positive control oligonucleotide probe containing a
consensus XBP-1s-binding motif or a probe containing the Zp CRE
motif in the absence () or presence () of anti-XBP-1 antibody
(Ab). (C) HeLa cells were transfected with Zp-LUC constructs with
either wild-type Zp or Zp containing a site-directed mutation in the
ZEB binding motif (ZEB) along with either empty vector or
vector expressing XBP-1s. Luciferase activity was measured 2 days
later.
FIG. 6. XBP-1s and HDAC inhibitors CaMKIV and valproic acid
activate lytic EBV gene expression. (A) HONE-1/EBV cells were
transfected with empty vector (), XBP-1s, or constitutively active
CaMKIV either alone or in combination, as indicated. Cell extracts
were examined by immunoblotting for the expression of the lytic EBV
proteins (BMRF1, R, and Z) and cellular -actin 2 days later. ,
present. (B) HONE-1/EBV cells were transfected with empty vector or
XBP-1s in the presence () or absence () or valproic acid (VPA; 1
mM). Extracts were analyzed by immunoblotting 2 days later for the
lytic EBV proteins (BMRF1, R, and Z) and cellular -actin.
7366 BHENDE ET AL. J. VIROL.
receptor engagement converts the CaMKIV protein into its
active form (40). Therefore, in B cells with type II or type III
latent EBV infection (in which LMP-1 is expressed), CaMKIV
(in addition to PKD) may function as a class II HDAC
inhibitor.
The transfection of HONE-1/EBV cells with a vector ex-
pressing a constitutively active form of CaMKIV by itself pro-
duced minimal expression of lytic EBV BMRF1, R, and Z
genes but greatly augmented the ability of transfected XBP-1s
to induce lytic viral gene expression (Fig. 6A). In addition,
transfected XBP-1s induced the expression of lytic EBV
BMRF1, R, and Z genes in the presence, but not the absence,
of a pharmacologic HDAC inhibitor, valproic acid (Fig. 6B).
These results suggest that it is the HDAC-inhibitory activity of
PKD and CaMKIV that allows them to complement XBP-1s in
reactivating EBV lytic infection.
XBP-1s expression contributes to lytic EBV gene expression
in early-passage LCLs. EBV-transformed B-cell lines (LCL
lines) usually secrete immunoglobulin (53), and early-passage
lines commonly express a small amount of lytic EBV genes
(20). XBP-1s may therefore contribute to the low-level consti-
tutive lytic EBV gene expression that occurs in some LCLs. To
determine if this is the case, we transfected early-passage LCLs
with an XBP-1 siRNA or equivalent amounts of a control
siRNA (Fig. 7). Cells transfected with the XBP-1 siRNA ex-
pressed less XBP-1 RNA than cells transfected with the con-
trol siRNA (Fig. 7A). Furthermore, the expression of the lytic
EBV Z and R genes was decreased in cells transfected with
XBP-1 siRNA, while the 2-microglobulin message was not
affected (Fig. 7B and C). In addition, the transfection of LCLs
with XBP-1 siRNA led to a decrease in the expression of the
EBV lytic BMRF1 gene as shown by the immunoblot in Fig.
7D. These results indicate that constitutive XBP-1s expression
in early-passage EBV-transformed B cells contributes to the
constitutive lytic viral gene expression in these cells.
DISCUSSION
Tightly latent EBV infection, which cannot easily be recog-
nized and eliminated by the immune response, enables long-
term persistence of the virus in the host. Latent EBV infection
is established in the long-lived memory B-cell compartment,
reducing the likelihood that the reservoir of latently infected
cells will ever be lost. However, to ensure that the virus is
transmitted from host to host, EBV must be periodically reac-
tivated to the lytic form of infection. Increasing evidence sug-
gests that the lytic form of EBV infection in humans occurs in
antibody-secreting plasma cells (30) and tonsillar epithelial
cells (42). Nevertheless, the molecular mechanism(s) underly-
ing the reactivation of lytic EBV infection during plasma cell
differentiation has not previously been explained. In this work,
we show that XBP-1, in combination with activated PKD, is
sufficient to induce lytic EBV gene expression in latently in-FIG. 7. XBP-1 is required for lytic EBV gene expression in
LCLs. EBV-transformed B cells were transfected with an siRNA
directed against XBP-1 or equal amounts of a control siRNA.
Results from two separate experiments are shown. (A) The level of
XBP-1 expression was examined by RT-PCR analysis 2 days after
siRNA delivery. PCR amplifications were performed using undi-
luted cDNA, as well as various dilutions of the cDNA, as indicated.
, present; , absent. (B) The expression level of the lytic viral Z
and R genes was examined by RT-PCR. (C) The expression of the
2-microglobulin (2-M) message was examined by RT-PCR. (D) The
expression of the early lytic EBV BMRF1 protein, as well as cellular
actin, was examined by immunoblot analysis 2 days after siRNA de-
livery.
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fected epithelial cells as well as LCLs. Furthermore, we dem-
onstrate that XBP-1 is required for the small amount of con-
stitutive lytic viral gene expression that occurs in early-passage
LCLs. Since XBP-1 is converted into its active (spliced) form
during plasma cell differentiation, while PKD is activated by
B-cell receptor engagement, these results help explain why the
lytic form of EBV infection is so strongly associated with
plasma cell differentiation in humans.
XBP-1 activation and plasma cell differentiation are intri-
cately linked. On the one hand, the activity of the XBP-1
transcription factor is dramatically enhanced by both transcrip-
tional and splicing mechanisms as B cells differentiate into
plasma cells. The production of antibodies by plasma cells
results in the accumulation of unfolded proteins in the endo-
plasmic reticulum (ER), leading to ER stress and activation of
the unfolded-protein response (UPR) (24). The UPR then
enhances XBP-1 function through at least two different mech-
anisms. First, the UPR induces proteolytic cleaving of the ER
protein ATF6, allowing the amino-terminal portion of the
protein to transit from the ER to the nucleus, where it binds to
the promoter of the XBP-1 gene and activates its transcription
(55, 56). Second, the UPR induces the homodimerization and
transphosphorylation of interferon gene regulatory element
1, converting it into an atypical splicing enzyme which medi-
ates the cytoplasmic splicing of XBP-1. Only this spliced form
of XBP-1, XBP-1s, contains a transcriptional activator domain
and can activate the transcription of downstream target genes
(2, 31).
On the other hand, XBP-1 is also clearly required for full
plasma cell differentiation, although its effect is downstream of
that of another essential plasma cell differentiation factor,
Blimp-1 (27, 46). B cells derived from XBP-1 knockout mice
mature normally but are unable to differentiate into antibody-
secreting plasma cells (43). The spliced form of XBP-1 not only
activates the transcription of numerous ER chaperone genes
(55) but also increases the size of the cellular mitochondrial,
ER, and secretory apparatus compartments (46). These down-
stream effects of XBP-1s, which presumably help the plasma
cell to efficiently produce and secrete large amounts of anti-
body (54, 55), may also promote the large-scale protein syn-
thesis required for the synthesis of lytic herpesvirus proteins.
Interestingly, cytomegalovirus was recently shown to modulate
and enhance certain aspects of XBP-1s function (22). By se-
lectively converting into the lytic form of viral infection in
plasma cells, EBV has likewise found a mechanism for ensur-
ing that sufficient XBP-1s activity is available in cells with the
lytic form of viral replication.
XBP-1s is known to activate most downstream target genes,
including ER chaperone genes and some major histocompat-
ibility complex class II genes, via direct binding to the promot-
ers of these genes (9, 25, 41, 54, 55). XBP-1s may also activate
transcription through indirect mechanisms, including enhanc-
ing the transcriptional effect of estrogen receptor alpha (12)
and inducing the expression of CCAAT/enhancer-binding pro-
tein beta (7). Our EMSA experiments suggest that XBP-1s
does not bind directly to Rp and binds minimally to the CRE
motif in Zp. We speculate that XBP-1s indirectly activates Zp
and/or Rp by inducing the transcription of a cellular factor that
activates one or both promoters or by interacting with one or
more cellular proteins that directly bind to Zp and/or Rp.
Dissecting the exact mechanism(s) by which XBP-1s increases
Z and R transcription will require further study.
Although XBP-1s alone activates the EBV Rp IE promoter
in reporter gene assays and high-level expression of R is suf-
ficient to induce lytic EBV infection in many cell types (includ-
ing HONE-1/EBV cells) (59), the combination of both XBP-1s
and activated PKD is required for the induction of lytic EBV
infection in latently infected HONE-1/EBV cells. PKD, which
belongs to a group of serine/threonine protein kinases (44), is
activated by B-cell receptor engagement via a pathway involv-
ing phospholipase C. Phospholipase C hydrolyzes phosphatidyl-
inositol (4,5)-bisphosphate to produce diacylglycerol, activat-
ing novel PKC isoforms, which in turn phosphorylate and
activate PKD (50, 52, 60). Activated PKD can then travel to
the nucleus and phosphorylate and inactivate class II HDACs.
The ability of PKD to disrupt viral latency in conjunction
with XBP-1s is likely mediated through the inhibition of class
II HDAC proteins, since a similar effect was observed using
two other HDAC inhibitors, CaMKIV and valproic acid. The
inhibition of class II HDAC proteins would be expected to
enhance the ability of XBP-1s to activate lytic viral gene tran-
scription in the context of the intact latent genome through at
least two different mechanisms. First, Rp is highly methylated
with an inactive (unacetylated) chromatin structure in the con-
text of the intact latent EBV genome in many cell lines (4, 6,
58). Chromatin accessibility to transcription factors is regu-
lated by the acetylation or deacetylation of nucleosomal his-
tones, and HDAC proteins inhibit the ability of many tran-
scription factors to activate target promoters by converting the
chromatin into a less accessible (deacetylated) form. The acet-
ylation of the chromatin around Rp (and possibly Zp) in the
context of the intact latent viral genome presumably enhances
the ability of XBP-1s to activate the promoter.
In addition, certain transcription factors, including members
of the MEF2 family, directly interact with class II (but not class
I) HDAC proteins and tether these HDACs to promoters with
MEF2-binding sites. Zp contains a series of MEF2D-binding
sites (known as ZI motifs), which function as negative regula-
tors when complexed with class II HDAC proteins (5, 13, 15,
18). The finding that the removal of the MEF2D sites in Zp
allowed XBP-1s alone to activate Zp without PKD strongly
suggests that PKD enhances XBP-1s activation of Zp at least
partially by inhibiting the interaction between MEF2D and
class II HDAC proteins.
As XBP-1s can also be activated by the UPR in non-B cell
types, it remains possible that XBP-1s also contributes to the
induction of lytic EBV infection in other cell types in response
to stimuli such as chemotherapy and radiation (13, 14). In any
event, the activation of the two EBV IE promoters by the
combination of two factors (spliced XBP-1 and activated PKD)
that are induced by B-cell receptor engagement and plasma
cell differentiation helps to ensure that EBV pathogenesis is
strongly linked to the state of B-cell maturation and activation.
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